Horizons of nanotechnology applications in female specific cancers

Balney, Rajitha; Malla, Rama Rao; Vadde, Ramakrishna; Kasa, Prameswari; Prasad, G. Lakshmi Vara; Farran, Batoul; Kumari, Seema; Pavitra, E.; Kamal, Mohammad Amjad; Raju, G. Seeta Rama; Peela, Sujatha; Nagaraju, Ganji Purnachandra

doi:10.1016/j.semcancer.2019.07.005

Cited by 24 publications

(15 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking into account these issues, in this review, we endeavor to summarize the investigation of novel small molecules together with the identification of new therapeutic targets against melanoma. Moreover, the application of nanotechnology to solve this problem has been an intelligent and fruitful strategy to improve selectivity for diseased tissues, enhance the efficacy and biochemical properties of active molecules and reduce pharmacoresistance [7,8,9]. Thus, the exploitation of new potential drugs for melanoma treatment is herein addressed, with the focus on lipid-based nanoformulations (e.g., liposomes) as efficient drug delivery systems.…”

Section: Introductionmentioning

confidence: 99%

Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma

2019

View full text Add to dashboard Cite

Melanoma is an aggressive form of skin cancer, being one of the deadliest cancers in the world. The current treatment options involve surgery, radiotherapy, targeted therapy, immunotherapy and the use of chemotherapeutic agents. Although the last approach is the most used, the high toxicity and the lack of efficacy in advanced stages of the disease have demanded the search for novel bioactive molecules and/or efficient drug delivery systems. The current review aims to discuss the most recent advances on the elucidation of potential targets for melanoma treatment, such as aquaporin-3 and tyrosinase. In addition, the role of nanotechnology as a valuable strategy to effectively deliver selective drugs is emphasized, either incorporating/encapsulating synthetic molecules or natural-derived compounds in lipid-based nanosystems such as liposomes. Nanoformulated compounds have been explored for their improved anticancer activity against melanoma and promising results have been obtained. Indeed, they displayed improved physicochemical properties and higher accumulation in tumoral tissues, which potentiated the efficacy of the compounds in pre-clinical experiments. Overall, these experiments opened new doors for the discovery and development of more effective drug formulations for melanoma treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma

2019

View full text Add to dashboard Cite

show abstract

“…After transfection, the cells were collected and resuspended in serum-free medium. Approximately 3×10 4 (migration assay) or 1×10 5 (invasion assay) of cells were placed the chamber and incubated for 24 h at 37 °C. Migrated or invaded cells in the bottom part of the chamber were xed using 20% methanol, and stained using 0.1% crystal violet (KeyGen, Guangzhou, China) for imaging and counting.…”

Section: Cell Invasion and Migration Assaysmentioning

confidence: 99%

“…High-quality medical services can aid timely screening and promote the early diagnosis of CC [4] . In addition, CC has a low 5year overall survival rate [5] . Hysterectomy is a widely used treatment for early CC, together with simultaneous radiotherapy and chemotherapy [6] .…”

Section: Introductionmentioning

confidence: 99%

Silencing of CMTM6 Inhibits the Proliferation and Migration of SiHa Cervical Cancer Cells by Inhibiting MAPK Signaling

Huang

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: CKLF like MARVEL transmembrane domain containing 6 (CMTM6) is an important programmed cell death 1 ligand 1 (PD-L1) regulator. CMTM6 was identified as an immune checkpoint inhibitor，that regulates tumor T cell activity in vivo and in vitro. The function of CMTM6 in cervical cancer, however, remains unclear. In addition, whether CMTM6 participates in ovarian cancer epithelial-mesenchymal transition (EMT) is unknown.Methods: Immunohistochemistry was used to detect CMTM6 expression in cervical cancer tissues and non-cancerous adjacent tissues. CMTM6 was knocked down and overexpressed, respectively, in the human SiHa cell line. Transwell and wound healing assays were used to assess cell migration and cell invasion. Western blotting was used to detect phosphorylated (p)-C-Jun N-terminal kinase (JNK)1/2, total (t)-JNK1/2, p-p38, t-p38, and EMT-related protein levels in Siha cells. In vivo lung transplantation tumor models were used to determine if CMTM6 upregulation in ovarian cancer cells could promote metastasis.Results: CMTM6 showed higher expression in human ovarian cancer tissues than in adjacent non-cancerous tissues. In vitro assays showed that CMTM6 promoted ovarian cancer cell invasion, migration, proliferation, and EMT via MAPK JNK/p38 signaling pathway activation. Stimulating CMTM6-overexpressing cells with MAPK JNK/p38 signaling antagonists reduced SiHa cell metastasis, invasion, proliferation and EMT. In a mouse model of lung metastasis, CMTM6 increased the metastasis of ovarian cancer. Conclusion: CMTM6 activates MAPK JNK/p38 signaling to enhance the EMT and metastasis of ovarian cancer cells. These results suggest CMTM6 as a molecular target for the prevention and treatment of ovarian cancer metastasis.

show abstract

“…Female reproductive organ cancers often develop silently without apparent symptoms, resulting in high morbidity and mortality (2). Because therapeutic strategies remain improving and the early detection tools are limited for most of these malignancies, female reproductive organ cancers are often diagnosed in their later stages which considerably impact the prognosis (3). In addition, some patients will develop chemoresistance and relapse after treatments due to the original cancers transform to more aggressive malignant phenotypes (4).…”

Section: Introductionmentioning

confidence: 99%

Melatonergic index as a prognostic biomarker of reproductive organ cancers: correlations with metabolic parameters as well as clock genes PER1 and TIMELESS

Chuffa¹,

Carvalho²,

Seiva³

et al. 2021

Melatonin Res.

View full text Add to dashboard Cite

Cancers of the reproductive organs are often hard to be detected, and patients’ survival rate drops considerably even when the tumor is removed. Based on the fact that melatonin levels are significantly lower in cancer cells than that in the healthy cells, and this melatonin suppression remains during tumor progression, we have examined a simple two-gene-based melatonergic system [the indices of melatonin synthesis and metabolism (ASMT:CYP1A1, ASMT:CYP1A2, ASMT:CYP1B1)] as a prognostic factor for reproductive organ cancer survival rate. RNA-seq data from The Cancer Genome Atlas (TCGA) of seven types of human reproductive organ tumors (n = 3571 samples) were analyzed. By stratifying the set of index values into high vs low risk, we observed that patients with a high melatonergic index had improved survival rates for cervical, ovarian, and endometrial cancers. Patients at high-risk (low melatonergic index) showed a trend of diagnosis of breast, prostate, and testicular cancers at the younger age, while patients with cervical, ovarian, and endometrial cancers presented with higher tumor staging. The melatonergic indices, especially the ASMT:CYP1B1, positively correlated with the clock gene PER1 while negatively correlated with the clock gene TIMELESS in all reproductive organ cancers. We further analyzed the correlation between the expression profiles of the melatonin-synthesizing enzyme (ASMT gene) with metabolic enzyme-encoding genes. Notably, LDHA, PDK1, and PDHA1 showed a higher correlation in male and female reproductive organ tumors, while IDH1, SDHB, GLS, and ATP1A1 had a positive correlation in breast, testicular, and endometrial cancers. These results have provided a comprehensive evaluation of the melatonergic system in relation to the reproductive organ tumor microenvironment and identified promising gene signatures as potential biomarkers for cancer diagnostics, prognostics, and therapeutics.

show abstract

Horizons of nanotechnology applications in female specific cancers

Cited by 24 publications

References 245 publications

Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma

Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma

Silencing of CMTM6 Inhibits the Proliferation and Migration of SiHa Cervical Cancer Cells by Inhibiting MAPK Signaling

Melatonergic index as a prognostic biomarker of reproductive organ cancers: correlations with metabolic parameters as well as clock genes PER1 and TIMELESS

Contact Info

Product

Resources

About